| 1345 |
National Cancer Institute |
Html |
en |
Where To Get Help When You Decide To Quit Smoking |
This fact sheet provides information about helpful resources for people who have decided to quit smoking. |
| pregnant smokers | 0.551074 |
| Monday | 0.355736 |
| health care provider | 0.663743 |
| Human Services | 0.458787 |
| smoking quitline | 0.772173 |
| past failures | 0.456683 |
| Control Research Branch | 0.617264 |
| online instant | 0.460766 |
| good sources | 0.488807 |
| fact sheet | 0.479049 |
| Disease Control | 0.471166 |
| Friday | 0.356769 |
| Spanish | 0.352479 |
| cessation counselors | 0.66457 |
| Handle Withdrawal Symptoms | 0.626098 |
| tobacco users | 0.460764 |
| local resources | 0.610693 |
| health care professionals | 0.901235 |
| Smokefree.gov Web site | 0.887035 |
| local cessation programs | 0.636749 |
| National Institutes | 0.468631 |
| a.m. | 0.357414 |
| toll-free number routes | 0.602386 |
| toll-free telephone quitline | 0.609664 |
| smoking-related questions | 0.477461 |
|
| NCI | 0.448064 |
| nicotine replacement products | 0.63931 |
| free materials | 0.471513 |
| Forever Free | 0.465092 |
| LiveHelp | 0.389817 |
| state-run quitlines | 0.469544 |
| support | 0.389277 |
| wide range | 0.469675 |
| resource information | 0.468257 |
| United States | 0.462426 |
| smokers | 0.602948 |
| specific action | 0.452212 |
| Express things | 0.451457 |
| smoking | 0.882754 |
| national resources | 0.480672 |
| free cessation assistance | 0.632049 |
| Eastern time | 0.627286 |
| smoking materials | 0.639653 |
| potential side effects | 0.490412 |
| Clear Horizons | 0.464946 |
| English | 0.352498 |
| science-driven tools | 0.47693 |
| one-on-one help | 0.476837 |
| information | 0.470963 |
|
CLICK HERE |
| 1440 |
National Cancer Institute |
Html |
en |
Genetics of Colorectal Cancer (PDQ®)–Health Professional Version |
Hereditary colorectal cancer syndromes include Lynch syndrome and several polyposis syndromes (familial adenomatous polyposis, MUTYH-associated polyposis, juvenile polyposis syndrome, Peutz-Jeghers syndrome, and serrated polyposis syndrome). Learn about the genetics, clinical manifestations, management, and psychosocial aspects of these and other hereditary colon cancer syndromes in this expert-reviewed summary. |
| hyperplastic polyps | 0.725031 |
| nondysplastic serrated polyps | 0.656585 |
| adenomatous polyps | 0.691874 |
| classic FAP burden | 0.649593 |
| colonic polyps | 0.652581 |
| colorectal cancer risk | 0.652487 |
| FAP patients | 0.932715 |
| colorectal cancer screening | 0.641111 |
| familial CRC risk | 0.634448 |
| duodenal adenomas | 0.717785 |
| polyps | 0.898156 |
| colorectal cancer | 0.915758 |
| large serrated polyps | 0.681431 |
| conventional hyperplastic polyps | 0.657048 |
| rectal cancer risk | 0.636363 |
| hereditary nonpolyposis colorectal | 0.723285 |
| CRC | 0.676743 |
| colorectal adenomatous polyps | 0.677785 |
| APC pathogenic variant | 0.710503 |
| familial adenomatous polyposis | 0.637625 |
| et al. | 0.674027 |
| adenomas | 0.856618 |
| study | 0.666989 |
| nonpolyposis colorectal cancer | 0.748743 |
| duodenal polyps | 0.793499 |
|
| polyp burden | 0.773382 |
| FAP family member | 0.659403 |
| hereditary colon cancer | 0.646397 |
| unselected CRC patients | 0.633325 |
| CpG island methylator | 0.649466 |
| Lynch syndrome patients | 0.681837 |
| pathogenic variants | 0.757278 |
| Advanced colorectal polyps | 0.671186 |
| serrated adenomas | 0.645858 |
| FAP families | 0.629309 |
| large adenomas | 0.639406 |
| Lynch syndrome | 0.829151 |
| FAP polyp burden | 0.677536 |
| colon cancer | 0.807611 |
| Abstract | 0.653383 |
| uncontrolled rectal polyps | 0.639399 |
| island methylator phenotype | 0.649038 |
| duodenal polyp burden | 0.68665 |
| FAP patients. | 0.679148 |
| SPS polyps | 0.632287 |
| family history | 0.768195 |
| cancer risk | 0.699194 |
| rectal cancer patients | 0.661401 |
| classic FAP | 0.64982 |
|
CLICK HERE |
| 1569 |
National Cancer Institute |
Html |
en |
Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of mycosis fungoides (including Sézary Syndrome). |
| red blood cells | 0.477836 |
| cancer treatment | 0.542958 |
| body | 0.529399 |
| type | 0.500535 |
| mycosis fungoides | 0.975868 |
| electron beam radiation | 0.477517 |
| PDQ cancer information | 0.525493 |
| clinical trial search | 0.486291 |
| white blood cells | 0.528751 |
| abnormal blood cells | 0.470219 |
| clinical trials | 0.793086 |
| Natural killer cells | 0.470828 |
| cancer information summary | 0.501852 |
| clinical trial | 0.600812 |
| mycosis fungoides cells | 0.530781 |
| patients | 0.476603 |
| blood cells | 0.579852 |
| skin electron beam | 0.532192 |
| malignant tumor cells | 0.48923 |
| NCI PDQ cancer | 0.469777 |
| Treatment Option Overview | 0.471891 |
| total skin electron | 0.534719 |
| radiation therapy | 0.663697 |
| Treatment Editorial Board | 0.471648 |
| beam radiation therapy | 0.484689 |
|
| treatment | 0.659413 |
| myeloid stem cell | 0.465408 |
| immature blood cells | 0.46931 |
| photodynamic therapy | 0.471883 |
| Recurrent mycosis fungoides | 0.52314 |
| mycosis fungoides spreads | 0.498418 |
| skin | 0.583221 |
| cancer cells | 0.698589 |
| lymphoid stem cell | 0.465897 |
| treatment clinical trials | 0.487816 |
| blood stem cells | 0.499083 |
| National Cancer Institute | 0.538216 |
| sézary syndrome | 0.849117 |
| normal cells | 0.5004 |
| new treatment | 0.509312 |
| Skin Cancer Treatment | 0.502202 |
| External radiation therapy | 0.473547 |
| metastatic mycosis fungoides | 0.5 |
| non-hodgkin lymphoma | 0.536949 |
| bone marrow | 0.486285 |
| cancer clinical trials | 0.50691 |
| stage | 0.517644 |
| cancer | 0.856203 |
| information | 0.542975 |
|
CLICK HERE |
| 1685 |
National Cancer Institute |
Html |
en |
Cannabis and Cannabinoids (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting. |
| cannabinoid receptor CB2 | 0.721549 |
| cancer cell proliferation | 0.723514 |
| opioid-treated cancer patients | 0.721253 |
| lung cancer | 0.774703 |
| testicular germ cell | 0.736506 |
| Cannabis trials | 0.713054 |
| endogenous cannabinoids | 0.733591 |
| bladder cancer | 0.72104 |
| clinical trials | 0.71653 |
| cannabinoid receptors | 0.745589 |
| advanced cancer patients | 0.745457 |
| CBD oromucosal spray | 0.730536 |
| cancer cell invasiveness | 0.726743 |
| Cancer Res | 0.716198 |
| cancer patients | 0.801404 |
| Investigational New Drug | 0.714731 |
| non-small cell lung | 0.751006 |
| effects | 0.733811 |
| colorectal cancer cell | 0.727697 |
| cancer chemotherapy | 0.737056 |
| cannabinoids | 0.838589 |
| et al. | 0.767053 |
| treatment | 0.713465 |
| study | 0.761272 |
| CBD | 0.77215 |
|
| United States | 0.780596 |
| Cannabis plant | 0.728018 |
| orally administered Cannabis | 0.721336 |
| Cancer Epidemiol Biomarkers | 0.717008 |
| cancer cell lines | 0.803788 |
| cannabinoid receptor | 0.74565 |
| THC | 0.76674 |
| Cannabis extract | 0.739506 |
| lung cancer chemotherapy | 0.709535 |
| cancer cell invasion | 0.72445 |
| breast cancer cell | 0.789227 |
| Cancer pain results | 0.7118 |
| cancer pain | 0.721348 |
| open-label extension study | 0.709343 |
| advanced cancer | 0.748132 |
| cell death | 0.806928 |
| Abstract | 0.744659 |
| cannabis | 0.92504 |
| germ cell tumors | 0.735413 |
| medicinal Cannabis | 0.751597 |
| cell lung cancer | 0.728336 |
| Cannabis species | 0.726958 |
| cancer | 0.952946 |
| Guidelines recommend cannabinoids | 0.714742 |
|
CLICK HERE |
| 1724 |
National Cancer Institute |
Html |
en |
HPV and Cancer |
A fact sheet about the link between human papillomaviruses (HPV) infection and cancer. |
| common HPV test | 0.550757 |
| HPV prophylactic vaccines | 0.525058 |
| HPV transmission | 0.523742 |
| HPV types | 0.851794 |
| new HPV infections | 0.590343 |
| HPV cause cancer | 0.569767 |
| new genital HPV | 0.595653 |
| Disease Control | 0.420832 |
| HPV vaccination coverage | 0.520008 |
| High-risk HPVs cause | 0.396129 |
| cervical cancer screening | 0.405825 |
| Sexually transmitted HPV | 0.603413 |
| cervical cancer | 0.502612 |
| high-risk HPV infections | 0.626562 |
| cervical human papillomavirus | 0.402943 |
| genital HPV infection | 0.55616 |
| human papillomavirus infection | 0.459361 |
| high-risk hpv types | 0.826201 |
| high-risk hpv | 0.840346 |
| human papillomavirus | 0.53728 |
| cancers | 0.432231 |
| HPV-positive oropharyngeal cancer | 0.40701 |
| HPV infections | 0.970786 |
| genital HPV infections | 0.683801 |
| contact. HPV infections | 0.593955 |
|
| HPV vaccination | 0.54978 |
| United States | 0.529252 |
| initial HPV infection | 0.546638 |
| oropharyngeal cancers | 0.43202 |
| dozen high-risk HPV | 0.602317 |
| HPV | 0.989222 |
| genital warts | 0.416311 |
| invasive cervical cancer | 0.399038 |
| sexually transmitted infections | 0.459394 |
| -negative oropharyngeal cancer | 0.400863 |
| precancerous cervical changes | 0.395202 |
| primary cervical cancer | 0.407999 |
| high-risk HPV type | 0.63373 |
| genital human papillomavirus | 0.479948 |
| high-risk hpvs | 0.421752 |
| HPV tests | 0.525251 |
| cervical intraepithelial neoplasia | 0.425761 |
| Sexually Transmitted Diseases | 0.450013 |
| abnormal cell changes | 0.409947 |
| persistent HPV infections | 0.582609 |
| respiratory tract tumors | 0.390546 |
| et al | 0.566033 |
| oropharyngeal cancer | 0.468234 |
| cell changes | 0.431517 |
|
CLICK HERE |
| 1810 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de páncreas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de páncreas. |
| resectable pancreatic | 0.421757 |
| Sin embargo | 0.468358 |
| largo plazo | 0.439685 |
| chemotherapy following curative | 0.48776 |
| Tumor Study Group | 0.478506 |
| curative resection | 0.550476 |
| fase iii | 0.665649 |
| Natl Cancer Inst | 0.419755 |
| after curative resection | 0.455925 |
| Arch Surg | 0.451242 |
| effective adjuvant combined | 0.42796 |
| gemcitabina versus | 0.464125 |
| quimiorradioterapia posoperatoria | 0.420132 |
| Gastrointestinal Intergroup | 0.4265 |
| Cameron JL | 0.507923 |
| periampullary region | 0.42716 |
| patients with | 0.44756 |
| randomized controlled | 0.421891 |
| Conlon KC | 0.442167 |
| Lillemoe KD | 0.42689 |
| EORTC gastrointestinal tract | 0.428698 |
| meses vs | 0.421884 |
| gastrointestinal tract | 0.431387 |
| following curative resection | 0.474649 |
| Yeo CJ | 0.5451 |
|
| M0 T2 | 0.428111 |
| M0 T1 | 0.424975 |
| chemotherapy after resection | 0.463442 |
| Regine WF | 0.420404 |
| M0 T3 | 0.428453 |
| pancreatic cancer | 0.97706 |
| as risk factors | 0.421112 |
| postoperative adjuvant chemoradiation | 0.455288 |
| versus gemcitabina | 0.456328 |
| Surg Oncol | 0.435512 |
| patients with resected | 0.42485 |
| Gastrointestinal Tumor Study | 0.48648 |
| páncreas estadio | 0.439198 |
| régimen off | 0.443587 |
| Grochow LB | 0.426604 |
| estadio iii | 0.623435 |
| Abrams RA | 0.46019 |
| Gy XRT | 0.450407 |
| Adjuvant chemotherapy with | 0.456373 |
| Stocken DD | 0.455773 |
| Oncology Group | 0.420611 |
| adjuvant combined | 0.442249 |
| quimioterapia posoperatoria | 0.432032 |
| 5-fluorouracil after curative | 0.42675 |
|
CLICK HERE |
| 2035 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de próstata (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad. |
| Cancer Events Trial | 0.485531 |
| principal hormona | 0.450019 |
| hiperplasia prostática benigna | 0.693996 |
| siguientes aspectos | 0.54196 |
| voluntarios sanos | 0.443459 |
| sistema urinario masculino | 0.492083 |
| protección baje | 0.460121 |
| sexuales masculinas | 0.54225 |
| caracterÃsticas sexuales masculinas | 0.494615 |
| productos lácteos | 0.532437 |
| National Cancer Institute | 0.461613 |
| causa problemas | 0.446148 |
| siguientes riesgos | 0.444876 |
| alto contenido | 0.439101 |
| vitamina e | 0.679303 |
| Instituto Nacional | 0.499716 |
| hormonas masculinas | 0.456898 |
|
| hormonas sexuales masculinas | 0.490983 |
| Cancer Prevention Trial | 0.881744 |
| próstata.ampliar próstata | 0.748136 |
| ensayo pcpt | 0.447994 |
| siguientes factores | 0.946442 |
| Physician Data Query | 0.60903 |
| Estados Unidos | 0.553599 |
| suficiente ejercicio | 0.453444 |
| prevención revisa | 0.462505 |
| Antecedentes familiares | 0.554865 |
| PDQ Prevención | 0.512729 |
| aparato reproductor masculino | 0.494928 |
| Prostate Cancer Prevention | 0.495264 |
| suficiente folato | 0.56107 |
| Prostate Cancer | 0.530877 |
| siguientes sumarios | 0.505076 |
|
CLICK HERE |
| 4134 |
National Cancer Institute |
Html |
es |
Papás que tienen a un niño con cáncer |
Información práctica para los padres, cuando un hijo tiene cáncer. Sugerencias para ayudar a los niños y a los padres a salir adelante y mantenerse fuertes; junto con respuestas a preguntas que padres e hijos hacen con frecuencia. |
| niño hable | 0.533769 |
| vidas—sus amistades | 0.451463 |
| tratamiento causa | 0.442235 |
| creatividad usted | 0.438948 |
| relaciones estables respete | 0.423362 |
| busque formas | 0.809977 |
|
| children with cancer | 0.982284 |
| niño lucha | 0.578927 |
| niño trabaje | 0.532596 |
| When Your Brother | 0.434468 |
| largas estancias | 0.426928 |
| tus doctores | 0.503446 |
|
CLICK HERE |
| 17289 |
National Cancer Institute |
Html |
es |
Servicios de apoyo |
Servicios disponibles para ayudarle a superar problemas durante el tratamiento del cáncer y después del mismo. |
|
|
CLICK HERE |
| 17293 |
National Cancer Institute |
Html |
es |
Falta de apetito |
Información y consejos para controlar la falta de apetito, un efecto secundario del tratamiento del cáncer. |
| siguientes medidas | 0.7116 |
| cáncer pdf | 0.657674 |
| causa dificultad | 0.715293 |
|
| complementos alimenticios | 0.63897 |
| suficiente lÃquido | 0.951874 |
| alto contenido | 0.653742 |
|
CLICK HERE |